Literature DB >> 19692627

Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?

Richarda M de Voer1, Fiona R M van der Klis, Laetitia E M Niers, Ger T Rijkers, Guy A M Berbers.   

Abstract

In The Netherlands, a single meningococcal serogroup C conjugate (MenCC) vaccination is administered to children at the age of 14 months. Here, we report the levels of MenC polysaccharide-specific antibodies in children at birth and at 3, 11, and 12 months of age and the presence of functional antibodies at 11 months of age, before infants receive their MenCC immunization. We observed a rapid decline in polysaccharide-specific antibodies after birth and no induction of naturally elicited polysaccharide-specific antibodies. Furthermore, at 11 months of age, no bactericidal antibodies are observed. These data indicate that these infants may be at risk in the period prior to MenCC immunization, if Neisseria meningitidis serogroup C starts to (re)circulate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692627      PMCID: PMC2756854          DOI: 10.1128/CVI.00274-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

1.  Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era.

Authors:  Caroline Trotter; Ray Borrow; Nick Andrews; Elizabeth Miller
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

2.  Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.

Authors:  Sabine C de Greeff; Hester E de Melker; Lodewijk Spanjaard; Leo M Schouls; Arie van Derende
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

3.  Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules.

Authors:  C Cameron; R Pebody
Journal:  Euro Surveill       Date:  2006-03-02

4.  Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany.

Authors:  M Wiese-Posselt; W Hellenbrand; A Siedler; C Mayer
Journal:  Euro Surveill       Date:  2006-09-07

5.  Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy.

Authors:  T J O'Dempsey; T McArdle; S J Ceesay; O Secka; E Demba; W A Banya; N Francis; B M Greenwood
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

6.  Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation.

Authors:  Philippe De Wals; Pierre Trottier; Jacques Pépin
Journal:  Vaccine       Date:  2006-02-21       Impact factor: 3.641

7.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

8.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Authors:  E Miller; D Salisbury; M Ramsay
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

9.  Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.

Authors:  Matthew D Snape; Dominic F Kelly; Ben Green; E Richard Moxon; Ray Borrow; Andrew J Pollard
Journal:  Pediatr Infect Dis J       Date:  2005-02       Impact factor: 2.129

10.  Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Judith E Nooitgedagt; Florens G A Versteegh; Johannes C M van Huisseling; Debbie M van Rooijen; Elisabeth A M Sanders; Guy A M Berbers
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.